OTC Markets EXMKT - Delayed Quote USD

Amarantus BioScience Holdings, Inc. (AMBS)

Compare
0.0001 0.0000 (0.00%)
At close: 12:26 PM EDT
Loading Chart for AMBS
DELL
  • Previous Close 0.0001
  • Open 0.0001
  • Bid --
  • Ask --
  • Day's Range 0.0001 - 0.0001
  • 52 Week Range 0.0001 - 0.0401
  • Volume 2,216
  • Avg. Volume 18,468
  • Market Cap (intraday) 63,040
  • Beta (5Y Monthly) 1.18
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0400
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

www.amarantus.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AMBS

View More

Performance Overview: AMBS

Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AMBS
80.00%
S&P 500
22.49%

1-Year Return

AMBS
80.00%
S&P 500
35.00%

3-Year Return

AMBS
98.75%
S&P 500
30.66%

5-Year Return

AMBS
99.33%
S&P 500
95.03%

Compare To: AMBS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AMBS

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    346.72k

  • Enterprise Value

    346.72k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -7.94M

  • Diluted EPS (ttm)

    -0.0400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    178

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: AMBS

View More

Company Insights: AMBS

Research Reports: AMBS

View More

People Also Watch